CN117045742B - 一种用于治疗神经血管病变的中药组合物及其制备方法 - Google Patents
一种用于治疗神经血管病变的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN117045742B CN117045742B CN202211646455.1A CN202211646455A CN117045742B CN 117045742 B CN117045742 B CN 117045742B CN 202211646455 A CN202211646455 A CN 202211646455A CN 117045742 B CN117045742 B CN 117045742B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 208000017376 neurovascular disease Diseases 0.000 title claims abstract description 5
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 10
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 10
- 241000173529 Aconitum napellus Species 0.000 claims abstract description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 8
- 240000000249 Morus alba Species 0.000 claims abstract description 8
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 8
- 229940023019 aconite Drugs 0.000 claims abstract description 8
- 235000006533 astragalus Nutrition 0.000 claims abstract description 8
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 5
- 241000756943 Codonopsis Species 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims description 24
- 230000008729 neurovascular lesion Effects 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 241000913745 Spatholobus Species 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 241000007126 Codonopsis pilosula Species 0.000 claims description 8
- 244000131316 Panax pseudoginseng Species 0.000 claims description 8
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 8
- 241000427159 Achyranthes Species 0.000 claims description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 7
- 235000011477 liquorice Nutrition 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 241000045403 Astragalus propinquus Species 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 7
- 208000024891 symptom Diseases 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 11
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract description 9
- 208000002193 Pain Diseases 0.000 abstract description 7
- 208000034783 hypoesthesia Diseases 0.000 abstract description 5
- 241001061264 Astragalus Species 0.000 abstract description 4
- 208000004044 Hypesthesia Diseases 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 4
- 210000004233 talus Anatomy 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 210000003414 extremity Anatomy 0.000 abstract description 2
- 201000000585 muscular atrophy Diseases 0.000 abstract description 2
- 231100000862 numbness Toxicity 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 240000000031 Achyranthes bidentata Species 0.000 abstract 1
- 241000533865 Callerya reticulata Species 0.000 abstract 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 230000020763 muscle atrophy Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 210000002683 foot Anatomy 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000003902 lesion Effects 0.000 description 5
- 241000207929 Scutellaria Species 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 210000000467 autonomic pathway Anatomy 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 229960005321 mecobalamin Drugs 0.000 description 2
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 2
- 235000007672 methylcobalamin Nutrition 0.000 description 2
- 239000011585 methylcobalamin Substances 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010059150 Cerebrosclerosis Diseases 0.000 description 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及药物组合物技术领域,尤其涉及一种用于治疗神经血管病变的中药组合物及其制备方法。一种用于治疗神经血管病变的中药组合物,由包括如下质量份数的组分制备而成:黄芪18~22份、党参17~21份、三七17~21份、鸡血藤15~19份、牛膝13~17份、附子13~17份、黄精11~15份、桂枝10~14份、桑葚8~12份、黄芩5~9份、知母3~7份和甘草3~7份。本发明药物配方严谨,并进行了大量临床资料验证,疗效确切,用于治疗糖尿病周围神经病变所出现的四肢麻木、疼痛、感觉迟钝、酸困、肌肉萎缩等证。诸药合用,气血同治,标本兼治,具有益气活血、通络止痛之功。
Description
技术领域
本发明涉及药物组合物技术领域,尤其涉及一种用于治疗神经血管病变的中药组合物及其制备方法。
背景技术
糖尿病是一组以高血糖为特征的代谢性疾病。高血糖则是由于胰岛素分泌缺陷或其生物作用受损,或两者兼有引起。糖尿病是长期存在的高血糖,导致各种组织,特别是眼、肾、心脏、血管、神经的慢性损害、功能障碍。
糖尿病神经病变是糖尿病最常见的慢性并发症之一,病变可累及中枢神经及周围神经,后者尤为常见。其中远端感觉神经病变是最常见的病变,占所有糖尿病神经病变的50%以上。
糖尿病神经病变病理改变广泛,主要可累及周围神经、自主神经、颅神经,脑及脊髓也可受累。早期表现为神经纤维脱髓鞘和轴突变性。Schwann细胞增生,随着病程进展,表现为轴突变性和髓鞘纤维消失,在髓鞘纤维变性的同时有再生丛的产生,随着病变的进展,再生丛密度降低,提示为一种不恰当修复,此种现象尤其在T2糖尿病中常见。有时,糖尿病神经病变的临床资料和电生理检查提示为慢性炎症性脱髓鞘性多神经病变,其主要改变是炎性浸润、脱髓鞘和轴突丧失,与特发性CIDP很难鉴别。自主神经受累时,主要表现为内脏自主神经及交感神经节细胞的变性。微血管受累的表现主要是内皮细胞增生肥大,血管壁增厚、管腔变窄、透明变性,毛细血管数目减少,严重者可发生小血管闭塞。脑部病变主要累及脑血管,易发生中风,尤其是脑梗塞,有些可发生脑萎缩和脑硬化。脊髓病变以后索损害为主,主要为变性改变。
目前多使用甲钴胺片、维生素B1、维生素B6、三磷酸腺苷、辅酶A、烟酸等治疗或预防,但副作用大或效果不明显,有许多中药复方也声称治疗糖尿病神经病变,但大多起效慢或没有经过验证,因此,亟需一种用于治疗神经血管病变的中药组合物。
发明内容
本发明的目的在于提供一种用于治疗神经血管病变的中药组合物。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种用于治疗神经血管病变的中药组合物,由包括如下质量份数的组分制备而成:黄芪18~22份、党参17~21份、三七17~21份、鸡血藤15~19份、牛膝13~17份、附子13~17份、黄精11~15份、桂枝10~14份、桑葚8~12份、黄芩5~9份、知母3~7份和甘草3~7份。
本发明还提供了所述的一种用于治疗神经血管病变的中药组合物的制备方法,包括如下步骤:
(1)将黄芪、党参、三七、鸡血藤、牛膝、附子、黄精、桂枝、桑葚、黄芩、知母和甘草混合研磨,得物料1;
(2)将物料1与水混合煎煮,过滤得滤液;
(3)将滤液减压浓缩得浸膏、干燥。
优选的,步骤(1)研磨后的物料过40~60目筛,收集筛选组分即为物料1。
优选的,步骤(2)所述物料1与水的质量比为1:4~8。
优选的,步骤(2)所述煎煮的时间为2~4h。
优选的,步骤(3)减压浓缩至60℃时相对密度为1.15~1.25的浸膏。
优选的,步骤(3)所述干燥的温度为55~65℃。
优选的,步骤(3)所述干燥的时间为3~5h。
与现有技术相比,本发明具有如下的有益效果:
1、本发明药物配方严谨,并进行了大量临床资料验证,疗效确切,用于治疗糖尿病周围神经病变所出现的四肢麻木、疼痛、感觉迟钝、酸困、肌肉萎缩等证。诸药合用,气血同治,标本兼治,具有益气活血、通络止痛之功。
2、糖尿病血管神经病变多为气虚导致的血瘀凝滞,气阴两虚,则血行不畅。本发明所述组合物以补气养阴,活血化瘀,通络,养血为主。其中,黄芪行使补气活血的作用,并配合党参、三七和鸡血藤,更助其活血通络的功效。
牛膝、桂枝作为臣药,行使逐瘀通经、引血下行、温通经脉的功效,可引导诸药通达全身;黄精补气养阴,也可助君药进一步发挥功效。
附子,散寒止痛;桑葚、补血滋阴,泻火解毒,止血;知母清热泻火,滋阴润燥,作为佐药,可缓解病人的疼痛,并弥补患者因病症导致的肝肾亏虚和精血耗损;黄芩则清热燥湿,甘草益气补中,解毒,起调和诸药的作用。
本发明所述组合物的君臣佐使关系总结如下:
君:黄芪、党参、三七、鸡血藤;
臣:牛膝、桂枝、黄精;
佐:桑葚、知母、附子;
使:黄芩、甘草。
具体实施方式
本发明提供了一种用于治疗神经血管病变的中药组合物,由包括如下质量份数的组分制备而成:黄芪18~22份、党参17~21份、三七17~21份、鸡血藤15~19份、牛膝13~17份、附子13~17份、黄精11~15份、桂枝10~14份、桑葚8~12份、黄芩5~9份、知母3~7份和甘草3~7份;优选由包括如下质量份数的组分制备而成:黄芪19~21份、党参18~20份、三七18~20份、鸡血藤16~18份、牛膝14~16份、附子14~16份、黄精12~14份、桂枝11~13份、桑葚9~11份、黄芩6~8份、知母4~6份和甘草4~6份;进一步优选由包括如下质量份数的组分制备而成:黄芪20份、党参19份、三七19份、鸡血藤17份、牛膝15份、附子15份、黄精13份、桂枝12份、桑葚10份、黄芩7份、知母5份和甘草5份。
本发明还提供了所述的一种用于治疗神经血管病变的中药组合物的制备方法,包括如下步骤:
(1)将黄芪、党参、三七、鸡血藤、牛膝、附子、黄精、桂枝、桑葚、黄芩、知母和甘草混合研磨,得物料1;
(2)将物料1与水混合煎煮,过滤得滤液;
(3)将滤液减压浓缩得浸膏、干燥。
在本发明中,步骤(1)研磨后的物料过40~60目筛,收集筛选组分即为物料1;优选为;进一步优选为;更优选为。
在本发明中,步骤(2)所述物料1与水的质量比为1:4~8;优选为1:5~7;进一步优选为1:6。
在本发明中,步骤(2)所述煎煮的时间为2~4h;优选为3h。
在本发明中,步骤(3)减压浓缩至60℃时相对密度为1.15~1.25的浸膏;优选为1.20。
在本发明中,步骤(3)所述干燥的温度为55~65℃;优选为57~63℃;进一步优选为59~61℃;更优选为60℃。
在本发明中,步骤(3)所述干燥的时间为3~5h;优选为4h。
下面结合实施例对本发明提供的技术方案进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
实施例1
一种用于治疗神经血管病变的中药组合物的制备方法,步骤如下:
(1)将黄芪18份、党参17份、三七17份、鸡血藤15份、牛膝13份、附子13份、黄精11份、桂枝10份、桑葚8份、黄芩5份、知母3份和甘草3份混合研磨,研磨后的物料过40目筛,收集筛选组分即为物料1;
(2)将物料1与水按质量比为1:4。混合煎煮2h,过滤得滤液;
(3)将滤液减压浓缩至60℃时相对密度为1.15的浸膏,55℃干燥3h,得中药粉。
实施例2
一种用于治疗神经血管病变的中药组合物的制备方法,步骤如下:
(1)将黄芪22份、党参21份、三七21份、鸡血藤19份、牛膝17份、附子17份、黄精15份、桂枝14份、桑葚12份、黄芩9份、知母7份和甘草7份混合研磨,研磨后的物料过60目筛,收集筛选组分即为物料1;
(2)将物料1与水按质量比为1:8。混合煎煮4h,过滤得滤液;
(3)将滤液减压浓缩至60℃时相对密度为1.25的浸膏,65℃干燥5h,得中药粉。
实施例3
一种用于治疗神经血管病变的中药组合物的制备方法,步骤如下:
(1)将黄芪20份、党参19份、三七19份、鸡血藤17份、牛膝15份、附子15份、黄精13份、桂枝12份、桑葚10份、黄芩7份、知母5份和甘草5份混合研磨,研磨后的物料过50目筛,收集筛选组分即为物料1;
(2)将物料1与水按质量比为1:6。混合煎煮3h,过滤得滤液;
(3)将滤液减压浓缩至60℃时相对密度为1.2的浸膏,60℃干燥4h,得中药粉。
实验例1
1、病例选择:选择患有糖尿病及周围神经血管病变的患者90人,平均分为三组,每组30人,男女比例1:1。
2、疗效判定标准:
1)周围神经病变:A.显效:临床症状消失,深浅感觉、膝腱反射基本恢复正常;B.有效:临床症状减轻,深浅感觉、膝腱反射未完全恢复;C.无效:临床症状和体征没有明显好转。
2)周围血管病变:A.显效:足背动脉搏动明显增强,皮温恢复正常,临床症状消失;B.有效:足背动脉搏动增强,脚部温度回升,临床症状基本消失;C.无效:临床症状,体征没有明显好转。
3、用药:
以实施例3得到的中药粉作为实验组;每次5g,早晚各一次。
对照组服用甲钴胺,按照说明书方法服用。
空白对照组:不使用任何药剂。
试验14d为一个疗程,共进行6个疗程。在第2个疗程,第4个疗程及实验完成后,分别统计各实验组的治疗效果,结果如表1所示。
表1
由表1记载的内容可知,经过6个疗程的治疗。以实验组的效果最好,治愈率可达83.3%。其对糖尿病引起的神经血管病变的治疗效果优异,且显著优于现有技术的药物的治疗效果60%。
实验例2
典型病例
1、胡某,男,患有糖尿病6年,双脚神经血管病变,双脚感觉基本消失,肌肉萎缩,长期服用硫辛酸药物治疗,并配合注射胰岛素,但治疗效果不佳。服用本发明中药粉3个疗程,症状明显缓解,双脚开始有感觉,服用7个疗程后,症状基本消失,双脚感觉基本恢复。
2、李某,女,患有糖尿病11年,2型糖尿病,糖尿病周围神经病变,病症为口干舌燥,四肢乏力,手足刺痛,并感觉减退,服用本发明中药粉,5个疗程,手足刺痛缓解,且感觉无异常。
3、谢某,男,患有糖尿病4年,患糖尿病周围神经病变1年,双足麻木冰凉,且感觉减退,双足轻度凹陷性浮肿,微刺痛。服用本发明中药粉6个疗程,症状消失,肢体感觉无异常,刺痛感消失。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (8)
1.一种用于治疗神经血管病变的中药组合物,其特征在于,由如下质量份数的组分制备而成:黄芪18~22份、党参17~21份、三七17~21份、鸡血藤15~19份、牛膝13~17份、附子13~17份、黄精11~15份、桂枝10~14份、桑葚8~12份、黄芩5~9份、知母3~7份和甘草3~7份。
2.权利要求1所述的一种用于治疗神经血管病变的中药组合物的制备方法,其特征在于,包括如下步骤:
(1)将黄芪、党参、三七、鸡血藤、牛膝、附子、黄精、桂枝、桑葚、黄芩、知母和甘草混合研磨,得物料1;
(2)将物料1与水混合煎煮,过滤得滤液;
(3)将滤液减压浓缩得浸膏、干燥。
3.根据权利要求2所述的一种用于治疗神经血管病变的中药组合物的制备方法,其特征在于,步骤(1)研磨后的物料过40~60目筛,收集筛选组分即为物料1。
4.根据权利要求2所述的一种用于治疗神经血管病变的中药组合物的制备方法,其特征在于,步骤(2)所述物料1与水的质量比为1:4~8。
5.根据权利要求2所述的一种用于治疗神经血管病变的中药组合物的制备方法,其特征在于,步骤(2)所述煎煮的时间为2~4h。
6.根据权利要求2所述的一种用于治疗神经血管病变的中药组合物的制备方法,其特征在于,步骤(3)减压浓缩至60℃时相对密度为1.15~1.25的浸膏。
7.根据权利要求2所述的一种用于治疗神经血管病变的中药组合物的制备方法,其特征在于,步骤(3)所述干燥的温度为55~65℃。
8.根据权利要求2所述的一种用于治疗神经血管病变的中药组合物的制备方法,其特征在于,步骤(3)所述干燥的时间为3~5h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211646455.1A CN117045742B (zh) | 2022-12-21 | 2022-12-21 | 一种用于治疗神经血管病变的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211646455.1A CN117045742B (zh) | 2022-12-21 | 2022-12-21 | 一种用于治疗神经血管病变的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117045742A CN117045742A (zh) | 2023-11-14 |
CN117045742B true CN117045742B (zh) | 2025-03-21 |
Family
ID=88659581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211646455.1A Active CN117045742B (zh) | 2022-12-21 | 2022-12-21 | 一种用于治疗神经血管病变的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117045742B (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101548997A (zh) * | 2005-10-08 | 2009-10-07 | 河北以岭医药研究院有限公司 | 作用于nei网络的药物在制备治疗血管病变的药物中的应用 |
CN112494546A (zh) * | 2020-12-22 | 2021-03-16 | 天津医科大学朱宪彝纪念医院 | 一种治疗糖尿病神经病变的光激发穴位透药剂及制备方法 |
-
2022
- 2022-12-21 CN CN202211646455.1A patent/CN117045742B/zh active Active
Non-Patent Citations (1)
Title |
---|
中西医结合治疗糖尿病周围神经病变84例总结;李继军;甘肃中医;20031130;16(11);27-28 * |
Also Published As
Publication number | Publication date |
---|---|
CN117045742A (zh) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1330347C (zh) | 中药滋补膏 | |
CN101461921B (zh) | 一种治疗妇科疾病的药物组合物 | |
CN104383115A (zh) | 一种治疗冠心病的中药制剂及其制备方法 | |
CN1895547B (zh) | 一种治疗2型糖尿病的药物及制备方法 | |
CN101485803B (zh) | 一种治疗月经不调及痛经的中药组合物 | |
CN101306138B (zh) | 一种治疗胸痹心痛的中药制剂及其制备方法 | |
CN104225166A (zh) | 一种治疗闭经的中药组合物及其制备方法 | |
CN117045742B (zh) | 一种用于治疗神经血管病变的中药组合物及其制备方法 | |
CN106075020A (zh) | 一种具有治疗糖尿病功效的灵芝复方颗粒剂 | |
CN104940597A (zh) | 一种治疗心肌梗死的中药组合物及其制备方法 | |
CN104225507A (zh) | 一种治疗脑溢血所致的肢体麻痹和疼痛的中药 | |
CN113041324A (zh) | 一种用于治疗气虚血瘀型糖尿病肾病的中药组合物及制备方法 | |
CN101199761B (zh) | 一种治疗动脉硬化的药物 | |
CN105168581A (zh) | 一种中药组合物用于制备治疗糖尿病肾病药物中的用途 | |
CN105902897A (zh) | 一种治疗胰腺癌的药物制剂及其用途 | |
CN1245197C (zh) | 治疗冠心病、病毒性心肌炎的中药制剂 | |
CN105232677A (zh) | 一种治疗心肌梗死的中药组合物及其制备方法 | |
CN104873911A (zh) | 一种辅助治疗脓毒症的内服中药 | |
CN100515462C (zh) | 治疗心、脑血栓性疾病的中药及制备方法 | |
CN107519261A (zh) | 一种治疗白血病的中药组合物及其制备方法 | |
CN104491602A (zh) | 一种治疗慢性心衰、早搏、心律失常的中药及其制备方法 | |
CN105456695A (zh) | 治疗内科疾病的药物组合物及其制备方法 | |
CN105456447A (zh) | 一种含有艾叶的具有活血化淤功能的中药组合物及其制备方法 | |
CN118987151A (zh) | 一种补中地黄汤的中药配方及其制备方法与应用 | |
CN111773310A (zh) | 一种益气养阴活血中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |